JP2012510987A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510987A5
JP2012510987A5 JP2011539117A JP2011539117A JP2012510987A5 JP 2012510987 A5 JP2012510987 A5 JP 2012510987A5 JP 2011539117 A JP2011539117 A JP 2011539117A JP 2011539117 A JP2011539117 A JP 2011539117A JP 2012510987 A5 JP2012510987 A5 JP 2012510987A5
Authority
JP
Japan
Prior art keywords
zaleplon
dosage form
biodegradable
layer
gastroretentive dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/007731 external-priority patent/WO2010064139A2/en
Publication of JP2012510987A publication Critical patent/JP2012510987A/ja
Publication of JP2012510987A5 publication Critical patent/JP2012510987A5/ja
Pending legal-status Critical Current

Links

JP2011539117A 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム Pending JP2012510987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12005108P 2008-12-04 2008-12-04
US61/120,051 2008-12-04
PCT/IB2009/007731 WO2010064139A2 (en) 2008-12-04 2009-10-19 Zaleplon gastroretentive drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231788A Division JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Publications (2)

Publication Number Publication Date
JP2012510987A JP2012510987A (ja) 2012-05-17
JP2012510987A5 true JP2012510987A5 (enExample) 2012-12-06

Family

ID=42232930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539117A Pending JP2012510987A (ja) 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム
JP2014231788A Expired - Fee Related JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014231788A Expired - Fee Related JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Country Status (11)

Country Link
US (2) US9693981B2 (enExample)
EP (1) EP2378883B1 (enExample)
JP (2) JP2012510987A (enExample)
KR (1) KR20110116004A (enExample)
CN (1) CN102300463B (enExample)
CA (1) CA2745741A1 (enExample)
ES (1) ES2562925T3 (enExample)
IL (1) IL213376A (enExample)
PL (1) PL2378883T3 (enExample)
WO (2) WO2010064100A1 (enExample)
ZA (1) ZA201104620B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106176678A (zh) 2008-04-18 2016-12-07 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
IN2012MN02923A (enExample) * 2010-06-01 2015-06-05 Rubicon Res Private Ltd
RS57426B1 (sr) * 2011-03-01 2018-09-28 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2854774A4 (en) 2012-06-01 2015-11-18 Lynn Health Science Inst Inc METHODS OF TREATING INSOMNIA
WO2014039951A1 (en) * 2012-09-10 2014-03-13 Novartis Ag Enteral pharmaceutical compositions
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2015038854A1 (en) 2013-09-13 2015-03-19 R.P. Scherer Technologies, Llc Encased-pellet tablets
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
JP6666858B2 (ja) 2014-06-11 2020-03-18 マサチューセッツ インスティテュート オブ テクノロジー 滞留構造体および関連方法
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US10881619B2 (en) * 2014-12-29 2021-01-05 Boston Scientific Scimed, Inc. Compositions, devices and methods for multi-stage release of chemotherapeutics
BR112017017729A2 (pt) 2015-02-20 2018-04-10 Osmotica Kereskedelmi Es Szolgaltato Kft forma de dosagem oral de liberação controlada de agonista de receptor gaba
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
JP7030052B2 (ja) 2015-12-08 2022-03-04 リンドラ セラピューティクス， インコーポレイティド 胃滞留システムのための幾何学的構成
AU2017268840B2 (en) 2016-05-27 2022-02-10 Nortiva Bio, Inc. Materials architecture for gastric residence systems
EP3481371A1 (en) * 2016-07-11 2019-05-15 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
AU2017336154B2 (en) 2016-09-30 2023-11-09 Nortiva Bio, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2018193337A2 (en) * 2017-04-18 2018-10-25 Actorius Innovations And Research Pvt. Ltd Polymer based formulation for release of drugs and bioactives at specific git sites
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
KR102333609B1 (ko) 2017-10-31 2021-12-01 주식회사 삼양홀딩스 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
MX2021011314A (es) * 2019-03-20 2021-12-10 Lyndra Therapeutics Inc Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.
JP2022525482A (ja) * 2019-03-20 2022-05-16 リンドラ セラピューティクス， インコーポレイティド 胃内滞留剤形用のコーティング
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
US11491125B1 (en) * 2021-09-29 2022-11-08 Amneal Pharmaceuticals Llc Baclofen formulations and methods of minimizing patient exposure to metabolite variations
AU2023209872A1 (en) * 2022-01-19 2024-08-01 Nortiva Bio, Inc. Dosage forms for gastric retention

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPH07179334A (ja) * 1993-12-22 1995-07-18 Sanei Touka Kk カプセル及びカプセル剤の製造方法
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
EP1064937A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20080081834A1 (en) * 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
KR100553887B1 (ko) * 2003-06-24 2006-02-24 삼성전자주식회사 수직 및 수평으로 광시야각을 갖는 영상표시용 스크린 및이를 구비하는 프로젝션 텔레비전
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
JP2007510733A (ja) * 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用
EP1535952B1 (en) * 2003-11-28 2013-01-16 Universite Louis Pasteur Method for preparing crosslinked polyelectrolyte multilayer films
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
JP4756835B2 (ja) * 2004-07-14 2011-08-24 キヤノン株式会社 生化学反応カートリッジ
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
CN101346073B (zh) * 2005-12-23 2013-02-13 卡夫食品环球品牌有限责任公司 提供基本上类似于由薄荷醇提供的感觉的组合物
PL2997953T3 (pl) 2006-01-18 2019-07-31 Intec Pharma Ltd. Przyrząd do podawania środka przyjmowanego doustnie
CA2642479C (en) * 2006-02-15 2014-08-19 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
EP1970056A1 (en) 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment

Similar Documents

Publication Publication Date Title
JP2012510987A5 (enExample)
JP6104873B2 (ja) ザレプロン胃内滞留性薬剤送達システム
CN111405895B (zh) 一种控释药物组合物及其制备方法
AU2008282900B2 (en) Pulsatile gastric retentive dosage forms
JP6062465B2 (ja) カルビドパ／レボドパ胃内滞留性薬物供給
JP2015028094A5 (enExample)
TWI324075B (en) Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
RU2554740C2 (ru) Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
Shashank et al. Approaches to increase the gastric residence time: floating drug delivery systems-a review
JP5161071B2 (ja) 胃酸分泌
RU2008151949A (ru) Фармацевтические лекарственные формы и композиции фенилэфрина для абсорбции в ободочной кишке
JP2018536007A5 (enExample)
JP2008533127A5 (enExample)
JP2014240435A (ja) 胃酸分泌を阻害するための組成物および方法
AU2009333300A1 (en) Oral formulations
CN104379138A (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
EP3866758B1 (en) Softgels with solid or gel-like polymeric fill matrix
JP2008516893A (ja) 多層錠剤および生体接着性剤形
Rabadia et al. The floating drug delivery system and its impact on calcium channel blocker: A review article
JP2017511350A5 (enExample)
Jain et al. An Insight on the Strategical Approach of Gastro-retentive Drug Delivery System
Mansuri et al. Glimpse of drug delivery systems for proton pump inhibitors
Benzine Enzymatically triggered polymeric drug delivery systems for colon targeting
JP2008150298A (ja) 溶解性を改善したジフェンヒドラミン含有医薬組成物
JP2013006843A (ja) 胃酸分泌